Bob Byrne from Northern California has severe hemophilia A. As a result of bad bleeds when he was younger, Byrne now suffers from arthritis and finds getting around difficult. Without anyone who can offer him care on a daily basis, he decided to get a service dog. MORE: Ten benefits of having…

Data from non-human primates suggest gene-editing therapy MGX-001 may be able to restore clinically meaningful levels of factor VIII (FVIII) after a single dose, supporting its potential as a one-time treatment for hemophilia A. Developer Metagenomi expects to meet with health authorities later this year to develop a strategy for…

Venture philanthropy fund Pathway to Cures (P2C)) has invested $500,000 in Five Liters, which is developing noninvasive, nonpharmacological neuromodulation therapies for treating inheritable blood and bleeding disorders, such as hemophilia and von Willebrand disease (VWD). “Investing in Five Liters’ early-stage research is a critical step in addressing unmet…

I’m training to become a chaplain. I want to work in a hospital setting one day, which will allow me to serve patients facing medical challenges. I’ll also have the privilege of walking with those who are in their last days. Sitting with people who are struggling at the hands…

Last year, at the Hemophilia Federation of America‘s Mild Matters Summit in Oklahoma, I attended a session led by physical therapist Nancy Durben that left a lasting impact. Durben guided a group on a leisurely walk, urging us to savor the experience — to relish the sound…

Planning for what happens after I die is such an uncomfortable topic that I want to run and hide. Somehow, just thinking about death makes it feel more real, even though I should have years of life left. Yet, I know that hemophilia A makes my life more fragile.

People are suffering. The country is divided. States are imposing limits on items that may be purchased, and businesses are closed. If there were ever a year to skip Thanksgiving, this would be it. At least, that is what some people think, but I am not one of them. It…

CSL Behring has closed an agreement giving it global commercialization and licensing rights to AMT-061, an experimental gene therapy for hemophilia B now being tested in a Phase 3 clinical trial. The therapy’s developer, uniQure, will receive an upfront cash payment of $450 million from CSL…

Preventive treatment with Hemlibra (emicizumab) sustainably improved physical health-related quality of life and led to fewer missed workdays among people with severe hemophilia A without inhibitors, an analysis of pooled data from two clinical trials found. According to researchers, these findings add to previous data showing that Hemlibra…

Sobi and Sanofi’s philanthropic organization, Foundation S, have announced an additional donation of up to 100 million international units (IUs) of clotting factor treatment to support the World Federation of Hemophilia (WFH) Humanitarian Aid Program. This is the second renewal of the 10-year partnership that will continue…